Doms № 1 -2022

Doms № 3 -2022

Pathological changes in the vessels of the lower extremities in obese patients

Lahoda D., Velychko V., Danylchuk H., Venher Y., Malcheniuk D.


Today, the problem of overweight and obesity is considered a worldwide pandemic. Thus, in the new 2022 report of the World Health Organization (WHO) on obesity in the European region, it is emphasized that the prevalence of overweight and obesity in the region has reached epidemic proportions and continues to grow. It is well known that obesity leads to the occurrence of cardiovascular diseases, oncological diseases, type 2 diabetes mellitus (T2D) and problems with the musculoskeletal system, which significantly affects the quality and length of a person’s life. According to research data, the relationship between body mass index and lower extremity joint pain has not been clearly established and remains controversial. While some studies have shown that obesity is associated with a higher prevalence and incidence of DPV, other researchers have failed to find a similar association. Some data even indicate an inverse relationship between BMI and prevalent DPV. Our study was retrospective in nature. According to the design, we analyzed 76 charts of patients with a diagnosis of “obesity” who underwent outpatient treatment at the office of the “School of Diabetes and Overweight” of the City Health Center of Odesa. The patients were offered to undergo ultrasound duplex scanning of the vessels of the NC along with an anthropometric examination. Comprehensive ultrasound was performed on the TOSHIBA APLIO MH diagnostic system (Japan). In addition, a certain cohort of patients was asked to take the Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ), which we adapted for Ukrainian patients. The CIVIQ questionnaire was developed by Launois with co-authors in 1996. This disease-specific questionnaire, namely DPV, has demonstrated its validity, excellent internal consistency, and high reproducibility. It is a valuable tool for assessing the quality of life of patients in an outpatient setting. During the survey, it was established that the most common comorbid pathologies were T2DM in 39 patients (51.31 %), AH-21 (27.63 %) and dyslipidemia in 29 patients (38.15 %). Drawing conclusions from such comorbidity, we can say that the majority of patients who took part in our study had metabolic syndrome, namely in 59 cases (77.63 %). Most of the patients namely 42 (55.26 %) patients had grade 3 obesity, 19 (25.00 %) grade 2 obesity and 15 (19.74 %) patients had grade 1 obesity. When asked about possible complaints from lower limbs, almost all patients, namely 73 (96.05 %) had at least one or several complaints, namely: a feeling of fullness in the lower extremities, heaviness, pain, cramps, fatigue, swelling, especially with standing and walking, intermittent lameness. Such patients were prescribed ultrasound of the lower extremities. With the help of ultrasound, the majority of patients were diagnosed with: chronic venous insufficiency and varicose veins of the lower limbs, 48 (65.75 %) and 25 (34.25 %), respectively. After obtaining the data of ultrasound lower limbs, a Spearman correlation regression analysis was conducted and it was determined that there is a direct close relationship between the degree of obesity severity and the development of chronic venous insufficiency and varicose veins of the NK (ρ=0.835; ρ=0.804, respectively). Considering not all of the above, there is a need to survey patients about the presence of complaints from the side of lower limbs with further possible more in-depth research, which may include ultrasound and the use of the CIVIQ questionnaire in outpatient practice. This will speed up the diagnosis and further management of patients with obesity and DPV. In addition, all patients living with obesity should be given recommendations on rational eating behavior and physical activity and, if necessary, recommend behavioral therapy.

Key words: obesity, diseases of peripheral vessels, comorbid pathology, chronic venous insufficiency, varicose veins.


  1. Management of a patient with varicose veins of the lower extremities, Voloshyn O.M., Suzdalenko, O.V., Gubka V.O., Machuskyi S.M., Pavlichenko V.D., Popova O.G., Rasul-Zade S.T., Ukrainian Medical Journal 1-2 (147-148) – I/IV 2022 DOI: 10.32471/umj.1680-3051.147.227698
  2. Order of the Ministry of Health of Ukraine dated August 5, 2009 No. 574 “On approval of protocols for providing medical care to patients with endocrine diseases.”
  3. Guideline 00499. Evaluation of a patient with obesity Guidelines based on evidence-based medicine. Created by DUODECIM Medical Publications, Ltd
  4. Оbesity in adults: a clinical practice guideline, Sean Wharton, David C.W. Lau, Michael Vallis, Arya M. Sharma and others CMAJ August 04, 2020 192 (31) E875-E891; DOI:
  5. Aghamohammadzadeh R, Greenstein AS, Yadav R, Jeziorska M, Hama S, Soltani F, Pemberton PW, Ammori B, Malik RA, Soran H, Heagerty AM (2013) Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity. J Am Coll Cardiol 62:128–135.
  6. Appelman Y, van Rijn BB, Ten Haaf ME, Boersma E, Peters SA. Sex differences in cardiovascular risk factors and disease prevention. Atherosclerosis. 2015;241(1):211–8.
  7. Baram A., Abdullah T. N., Taha A. Y. Femoropopliteal bypass for chronic lower limb ischemia: A prospective cohort study and single center cases series. International Journal of Surgery Open. 2019. Vol. 21. P. 1–6.
  8. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Goldbourt U. Epidemiology of intermittent claudication in middle-aged men. Am J Epidemiol. 1994;140(5):418–30.
  9. Criqui MH, Vargas V, Denenberg JO, Ho E, Allison M, Langer RD, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation. 2005;112(17):2703–7.
  10. Frank U., Nikol S., Belch J., et al. ESVM Guideline on peripheral arterial disease. Vasa. 2019. Vol. 48, No. Supplement 102. P. 1–79.
  11. Hooi JD, Stoffers HE, Knottnerus JA, Rinkens PE, van Ree JW. Asymptomatic peripheral arterial occlusive disease and erection problems. Br J Gen Pract. 2001;51(466):404. 
  15. Ix JH, Biggs ML, Kizer JR, Mukamal KJ, Djousse L, Zieman SJ, et al. Association of body mass index with peripheral arterial disease in older adults: the Cardiovascular Health Study. Am J Epidemiol. 2011;174(9):1036–43. 
  16. Kalteis M. ,  Berger I. ,  Messie S. ,Werndl,  Pistrich R.,  Schimetta W. ,  Pölz W., et al. High ligation combined with stripping and endovenous laser ablation of the great saphenous vein: early results of a randomized controlled study J Vasc Surg, 47 (4) (2008), pp. 822-829
  17. Lozano F.S. ,  Launois R. Quality of life (Spain and France): validation of the chronic venous insufficiency questionnaire (CIVIQ) Methods Find Exp Clin Pharmacol, 24 (7) (2002), pp. 425-429
  18. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143(6):961–5.
  19. Neglén P. , Hollis K.C,  Raju S. Combined saphenous ablation and iliac stent placement for complex severe chronic venous disease J Vasc Surg, 44 (4) (2006), pp. 828-833
  20. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;45(6):1185–91.
  21. Zheng ZJ, Rosamond WD, Chambless LE, Nieto FJ, Barnes RW, Hutchinson RG, et al. Lower extremity arterial disease assessed by ankle-brachial index in a middle-aged population of African Americans and whites: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Prev Med. 2005;29(5 Suppl 1):42–9.
  1. R. Seaquist, J. Anderson, B. Childs et al., “Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society,” Diabetes Care, vol. 36, no. 5, pp. 1384-1395, 2013.
  2. Kunt and F. J. Snoek, “Barriers to insulin initiation and intensification and how to overcome them,” International Journal of Clinical Practice, vol. 63, pp. 6-10, 2009.3.
    P. E. Cryer, S. N. Davis, and H. Shamoon, “Hypoglycemia in diabetes,” Diabetes Care, vol. 26, no. 6, pp. 1902-1912, 2003.
  3. Bohn, W. Kerner, J. Seufert et al., “Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: analysis of real-life data from the DPV registry from Germany and Austria,” Diabetes Research and Clinical Practice, vol. 115, pp. 31-38, 2016.
  4. M. Bala, E. Placzkiewicz-Jankowska, W. Lesniak et al., “Leczenie i spelnianie celów leczenia u polskich chorych na cukrzycç typu 2 od ponad 10 lat – wyniki badania ARE- TAEUS2-Grupa,” Endokrynologia Polska, vol. 65, no. 3, pp. 158-168, 2014.
  5. C. Cowie, “Diabetes diagnosis and control: missed opportunities to improve health: the 2018 Kelly West Award Lecture,” Diabetes Care, vol. 42, no. 6, pp. 994-1004, 2019.
  6. J. Lipska, X. Yao,J. Herrinet al., “Trendsindrug utilization, glycemic control, and rates of severe hypoglyce- mia, 20062013,” Diabetes Care, vol. 40, no. 4, pp. 468-475, 2017.
  7. Leiter, J. Yale, J. Chiasson, S. Harris, P. Kleinstiver, and L. Sauriol, “Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management,” Diabetes, vol. 29, pp. 186-192, 2005.
  8. Rys, P. Wojciechowski, A. Rogoz-Sitek et al., “Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus,” Acta Diabetologica, vol. 52, no. 4, pp. 649-662, 2015.
  9. Goldman and J. R. White Jr., “New insulin glargine 300 U/mL forthe treatment of type 1 and type2 diabetes mellitus,” The Annals of Pharmacotherapy, vol. 49, no. 10, pp. 1153-1161, 2015.
  10. Ritzel, R. Roussel, A. Giaccari, J. Vora,C. Brulle-Wohlhueter, and H. Yki-Järvinen, “Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 1 00 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes,”Diabetes,Obesity&Metabolism, vol. 20, no. 3, pp. 541-548, 2018.
  11. Seufert, A. Fritsche, H. Anderten, K. Pegelow, S. Pscherer, and M. Pfohl, Switching to Insulin Glargine 300 U/mL (Gla- 300) Improves Glycemic Control and Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes (T2DM)
  12. on Basal Insulin Supported Oral Therapy, vol. 67, 78th Scientific Sessions of American Diabetes Association, 2018, (Poster 1020-P).
  13. Gupta, H. Wang, N. Skolnik et al., “Treatment dosing patterns and clinical outcomes for patients with type 2 diabetes starting or switching to treatment with insulin glargine (300 units per milliliter) in a real-world setting: a retrospective observational study,” Advances in Therapy, vol. 35, no. 1, pp. 43-55, 2018.
  14. Hidvegi and P. Stella, Effectiveness of Insulin Glargine 300 U/mL Used as a Part of Basal Bolus Therapy in People with T2DM-TOUJEO 6M. Real World Data from Hungary, 78th Scientific Sessions of American Diabetes Association, 2018, (Poster 1049-P).
  15. Freemantle, E. Chou, C. Frois et al., “Safety and efficacy of insulin glargine 300 U/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis,” BMJ Open, vol. 6, no. 2, article e009421, 2016.
  16. C. Riddle, G. B. Bolli, M. Ziemen, I. Muehlen-Bartmer, F. Bizet, and P. D. Home, “New insulin glargine 300 units/ mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1),” Diabetes Care, vol. 37, no. 10, pp. 2755-2762, 2014.
  17. Pettus, R. Roussel, F. L. Zhou et al., “Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U/mL versus first and second-generation basal insulin analogs: the real-world LIGHTNING study,” Diabetes Therapy, vol. 10, no. 2, pp. 617-633, 2019.